The increasing use of immunotherapies in cancer will lead to more cases of steroid-refractory colitis that can only be treated with infliximab, gastroenterologists predict. But the anti-TNF drug is not available on the PBS or hospital formularies for the treatment immunotherapy-related colitis, and so patients may be denied access to effective treatment for the serious, ...
Increase in immunotherapy colitis highlights need for infliximab
By Michael Woodhead
23 Jun 2020